HomeCompareIVRA vs MRK

IVRA vs MRK: Dividend Comparison 2026

IVRA yields 17.39% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IVRA wins by $5.4K in total portfolio value
10 years
IVRA
IVRA
● Live price
17.39%
Share price
$15.98
Annual div
$2.78
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62.1K
Annual income
$5,047.06
Full IVRA calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — IVRA vs MRK

📍 IVRA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIVRAMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IVRA + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IVRA pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IVRA
Annual income on $10K today (after 15% tax)
$1,478.18/yr
After 10yr DRIP, annual income (after tax)
$4,290.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $4,038.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IVRA + MRK for your $10,000?

IVRA: 50%MRK: 50%
100% MRK50/50100% IVRA
Portfolio after 10yr
$59.5K
Annual income
$7,422.60/yr
Blended yield
12.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

IVRA
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IVRA buys
0
MRK buys
0
No recent congressional trades found for IVRA or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIVRAMRK
Forward yield17.39%2.76%
Annual dividend / share$2.78$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$62.1K$56.8K
Annual income after 10y$5,047.06$9,798.13
Total dividends collected$32.8K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IVRA vs MRK ($10,000, DRIP)

YearIVRA PortfolioIVRA Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,439$1,739.04$11,206$366.19+$1.2KIVRA
2$15,331$2,021.68$12,650$502.35+$2.7KIVRA
3$18,733$2,328.76$14,407$694.19+$4.3KIVRA
4$22,704$2,659.34$16,585$967.82+$6.1KIVRA
5$27,306$3,012.16$19,342$1,363.89+$8.0KIVRA
6$32,603$3,385.64$22,913$1,947.19+$9.7KIVRA
7$38,663$3,777.96$27,662$2,823.89+$11.0KIVRA
8$45,556$4,187.11$34,159$4,173.35+$11.4KIVRA
9$53,356$4,610.90$43,337$6,308.80+$10.0KIVRA
10$62,138$5,047.06$56,776$9,798.13+$5.4KIVRA

IVRA vs MRK: Complete Analysis 2026

IVRAStock

The Invesco Real Assets ESG ETF (Fund) is an actively-managed exchanged-traded fund that seeks capital appreciation with a secondary objective of current income. The Fund seeks to achieve its investment objective by investing primarily in exchange-traded equity securities of “real assets” companies located in North America that meet high environmental, social and governance (ESG) standards. To meet these standards, the Fund employs a proprietary ESG screening process on all investment opportunities. First, the Fund screens the issuers in the investment universe for exclusions, such as substantial involvement (i.e. generating more than 0-10% of the issuer’s revenue) in tobacco, alcohol, controversial and conventional weapons, recreational cannabis, extraction of thermal coal, extraction of fossil fuels from unconventional sources, and operations of private prisons. Issuers are also excluded based on their non-compliance with the United Nations Global Compact principals. Next, investment opportunities are evaluated on multiple ESG factors under each individual pillar of the ESG framework and real assets sector. The individual pillars include, but are not limited to: environmental pillar (“E”) factors: natural resources, pollution and waste, supply chain impact, and environmental opportunities; social pillar (“S”) factors: workforce, community, product responsibility, and human rights; governance pillar (“G”) factors: management, shareholders, board of directors, auditors, regulatory issuers, corporate social responsibility strategy, anti-corruption, and business ethics. Each ESG pillar and investment opportunity are considered separately and neither weighs each pillar equally, nor consistently emphasizes one pillar over another. “Real assets” are characterized by having physical attributes, including real estate, infrastructure, natural resources and timber. Real assets companies are considered companies that are either principally engaged in real estate, infrastructure, natural resources or timber industries, or support such businesses.Important Notice Regarding Changes to the Fund’s Structure and Management Fee Effective May 13, 2025, The Fund transitioned from a "non-transparent" ETF, which does not publicly disclose its portfolio holdings daily pursuant to an exemptive order from the U.S. Securities and Exchange Commission (the “Order”) to a "transparent" ETF that will disclose its portfolio holdings daily and operate in reliance on Rule 6c-11 under the Investment Company Act of 1940, as amended. In connection with this change to a fully “transparent” structure, the Fund will change as follows:The Fund’s investment objective and principal strategies will remain unchanged despite these structural adjustments and fee reduction.For additional information regarding the unique attributes and risks of the ETF, see the Risk & Other Information section below.

Full IVRA Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this IVRA vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IVRA vs SCHDIVRA vs JEPIIVRA vs OIVRA vs KOIVRA vs MAINIVRA vs JNJIVRA vs ABBVIVRA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.